ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in patients with Merkel cell carcinoma and lymph node metastases.
Journal of Clinical Oncology · 2026-06-03
Response-focused analyses of the impact of circadian rhythm on efficacy of first-line immunotherapy in melanoma.
Journal of Clinical Oncology · 2026-05-28
Combining HC-7366 with belzutifan in patients with renal cell carcinoma to alter tumor and microenvironment: Pharmacokinetic and pharmacodynamic (PK/PD) analysis of a phase 1b study.
Journal of Clinical Oncology · 2026-05-27
Case Report: donor cell-derived leukemia after allogeneic stem cell transplantation for metastatic renal cell carcinoma
Frontiers in Immunology · 2026-05-26
Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases: A Case-Based Radiosurgery Society Review
Practical Radiation Oncology · 2026-04-01
Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.
Journal of Clinical Oncology · 2026-03-01
608 A phase I clinical trial of a personalized neoantigen vaccine in PD-1 inhibitor refractory metastatic melanoma
Regular and Young Investigator Award Abstracts · 2025-11-01
From surgery to systemic therapy in von Hippel-Lindau disease: insights from extended follow-up of LITESPARK-004
Translational Andrology and Urology · 2025-11-01
Abstract B006: Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)
Molecular Cancer Therapeutics · 2025-10-22 · 2 citations
30Meta-analysis of single-cell RNA sequencing of tumor-infiltrating T-cells in clear cell renal cell carcinoma reveals distinct phenotypes and prediction markers of expanded T-cell clonotypes
The Oncologist · 2025-10-01
22Final results of the phase 3 COSMIC-313 study comparing first-line cabozantinib plus nivolumab and ipilimumab with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma
The Oncologist · 2025-10-01
17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)
The Oncologist · 2025-10-01 · 1 citations
A mixed-method analysis of oncologist-patient communications about immune checkpoint inhibitors (COACH)
The Oncologist · 2025-07-01 · 1 citations
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
Journal of Clinical Oncology · 2025-05-28 · 1 citations
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
ESMO Open · 2025-05-01 · 57 citations
Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313.
Journal of Clinical Oncology · 2025-02-10 · 12 citations
Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
Journal of Clinical Oncology · 2025-02-10 · 5 citations
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
Journal of Clinical Oncology · 2025-02-10
Genetic and Iatrogenic Defects in Peripheral Tolerance Associated with Anti-Nephrin Antibody-Associated Minimal Change Disease
Glomerular Diseases · 2025-01-09 · 2 citations
Belzutifan for the treatment of renal cell carcinoma
Therapeutic Advances in Medical Oncology · 2025-01-01 · 21 citations